The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant platin and bevacizumab in triple-negative breast cancer.
P. Kern
No relevant relationships to disclose
F. Otterbach
No relevant relationships to disclose
H. C. Kolberg
No relevant relationships to disclose
D. Pott
No relevant relationships to disclose
A. Kalisch
No relevant relationships to disclose
R. Kimmig
No relevant relationships to disclose